On the stock market since 2016, it operates in the world of health and science. It has 1,796 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
Average growth of 11% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $1.3B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 83% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 9% a year on average.
There is $1.4B in the vault; even if every debt were paid off, $1.3B would remain.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, HCM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HCM is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.